Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy

This publication has 91 references indexed in Scilit:

• Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific Immunotherapy
  Molecular Therapy, 2010
• Differences in Brain Volume, Hippocampal Volume, Cerebrovascular Risk Factors, and Apolipoprotein E4 Among Mild Cognitive Impairment Subtypes
  Archives of Neurology, 2009
• Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus
  Molecular Therapy, 2009
• Everyday functioning in mild cognitive impairment and its relationship with executive cognition
  International Journal of Geriatric Psychiatry, 2009
• Longitudinal Changes in Memory and Executive Functioning are Associated with longitudinal change in instrumental activities of daily living in older Adults
  The Clinical Neuropsychologist, 2009
• A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer
  Molecular Therapy, 2009
• Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy
  Molecular Therapy, 2008
• Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide
  Molecular Therapy, 2008
• Frequency and course of mild cognitive impairment in a multiethnic community
  Annals of Neurology, 2008
• Cognitive and neuroimaging predictors of instrumental activities of daily living
  Journal of the International Neuropsychological Society, 2007